Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The profound effects of solid tumour-induced B cell dysregulation

ABSTRACT: Solid tumours evade immunosurveillance through a plethora of mechanisms. It remains elusive how the development and functions of B cells vary in different tumour contexts. Here, we observed distinct patterns of B cell abnormality in triple-negative breast cancer and termed these patterns “tumour-induced B cell abnormality” type (TiBA). TiBA results from disrupted early B cell development in the bone marrow, which is associated with abnormal myelopoiesis. This study highlights the heterogeneity of tumour-induced systemic changes on B cells and lays foundation for the precision treatment of patients with different B cell abnormalities.

ORGANISM(S): Mus musculus

PROVIDER: GSE222854 | GEO | 2023/11/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The profound effects of solid tumour-induced B cell dysregulation [PyMT-N tumor]

Project description:Solid tumours evade immunosurveillance through a plethora of mechanisms. It remains elusive how the development and functions of B cells vary in different tumour contexts. Here, we observed distinct patterns of B cell abnormality in triple-negative breast cancer and termed these patterns “tumour-induced B cell abnormality” type (TiBA). TiBA results from disrupted early B cell development in the bone marrow, which is associated with abnormal myelopoiesis. This study highlights the heterogeneity of tumour-induced systemic changes on B cells and lays foundation for the precision treatment of patients with different B cell abnormalities.

2024-08-13 | GSE274772 | GEO

The profound effects of solid tumour-induced B cell dysregulation

Project description:The profound effects of solid tumour-induced B cell dysregulation

| PRJNA923661 | ENA

Gene expression in human myeloid cells

Project description:Human myelopoiesis is an exciting biological model for cellular differentiation since it represents a plastic process where pluripotent stem cells gradually limit their differentiation potential, generating different precursor cells which finally evolve into distinct terminally differentiated cells. This study aimed at investigating the genomic expression during myeloid differentiation through a computational approach that integrates gene expression profiles with functional information and genome organization. The genomic distribution of myelopoiesis genes was investigated integrating transcriptional and functional characteristics of genes. The analysis of genomic expression during human myelopoiesis using an integrative computational approach allowed discovering important relationships between genomic position, biological function and expression patterns and highlighting chromatin domains, including genes with coordinated expression and lineage-specific functions. Keywords: cell differentiation Gene expression data from 20 experiments for 8 different cell types of the human myelopoietic lineage were used to generate an integrated myelopoiesis dataset.

2008-12-10 | E-GEOD-12803 | biostudies-arrayexpress

Genome-wide SNP Microarray Mapping in Basal Cell Carcinomas Unveils Uniparental Disomy as a Key Somatic Event.

2005-07-21 | GSE2959 | GEO

Genotyping of human basal cell carcinomas unveils uniparental disomy as a key domatic event.

Project description:Affymetrix 10K SNP mapping arrays were used to profile 14 basal cell carcinomas (BCCs) with matched blood DNA samples. Loss of heterozygosity (LOH) and copy number abnormality (CNA) profiles were derived from each tumour-blood pair. Experiment Overall Design: 14 BCC/Blood pairs were used in this study to obtain genome-wide SNP profiles. By comparing tumour and blood DNA, LOH for each SNP could be obtained. Signal intensity for each SNP were used to deternime CNA.

2008-06-12 | E-GEOD-2959 | biostudies-arrayexpress

Proteins identified from E. coli MG1655-origined OMVs in the paper of “On-demand Editing Macrophages Enable Specific Phagocytosis and Drug Exosome Generation for Solid Tumour Cytotherapy”

Project description:Cytotherapy is a revolutionary therapeutic agent representing the forefront of current cancer therapy, but its poor efficacy in the treatment of solid tumours remains challenging. Integration of tumour infiltration, targeted elimination and tumour microenvironment (TME) regulation functions in designing effective cytopharmaceuticals for solid tumours is necessary. Here, we designed on-demand editing macrophages (RILO-M1-G) constructed by surface glypican-3 (GPC3) peptide anchoring and inner R848/INCB024360-lipid particle (RILO) packing to combat hepatocellular carcinoma (HCC). Based on the tumour tendency and deep penetration of macrophages, the anchored GPC3 peptide on the membrane surface promoted macrophage-tumour cell recognition, thus enhancing specific tumour targeting and phagocytosis of tumour cells with high GPC3 expression. The packed RILOs were wrapped by C16-ceramide fused Escherichia coli-originated outer membrane vesicles (OMVs). OMVs facilitated RILO internalization through caveolin-mediated endocytosis to maintain a suitable nanostructure, C16-ceramide induced membrane invagination and exosome generation, leading to the release of packed RILOs through exosomes. These exosomes containing the TLR7/8 agonist R848 and IDO1 inhibitor INCB024360 enabled remodelling of the immunosuppressive TME by regulating the tumour-associated macrophage phenotype and enhancing T-cell viability. Furthermore, treatments with RILO-M1-G exerted remarkable therapeutic efficacy in a H22 tumour-bearing mouse model, rechallenged tumour model and orthotopic HCC mouse model compared with that of first-line HCC therapy. Overall, RILO-M1-G offered a new cytotherapeutic strategy for meeting the clinical demands of solid tumour treatment.

2023-09-08 | PXD045220 |

Single cell RNA-seq from 10X for a living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity

Project description:We validated fifteen models from “living biobank” to provide models that support interrogation of Chromosome Instability and to evaluate novel therapeutics. Single cell RNA-seq was performed on tumour and stromal cells from 4 patients with ovarian cancer to establish gene expression profile differences between the two cell types and also heterogeneity within the tumour population. The samples used were AS38b, AS59, AS74-1, AS79, they are grown in OCMI media supplemented with 5% hyclone serum (AS38, AS59) or 5% FBS (AS74, AS79) in 5% CO2 and 5% O2. At 37C

2020-01-23 | E-MTAB-8559 | biostudies-arrayexpress

Gene expression in human myeloid cells

2008-12-10 | GSE12803 | GEO

CREBBP is a novel tumour suppressor in solid tumours

Project description:The contribution of the majority of frequently mutated genes to tumourigenesis is not fully defined. Many aggressive human cancers, such as triple negative breast cancers (TNBCs), have a poor prognosis and lack tractable biomarkers and targeted therapeutic options. Here, we systematically characterize loss-of-function mutations to generate a functional map of novel driver genes in a 3-dimensional model of breast cancer heterogeneity that more readily recapitulates the unfavourable tumour microenvironment in vivo. This identified the histone acetyltransferase CREBBP as a potent tumour suppressor gene whose silencing provided a 3D-specific growth advantage only under oxygen and nutrient deplete conditions. CREBBP protein expression was altered in a substantial proportion of TNBCs as well as several other solid tumours, including endometrial, bladder, ovarian and squamous lung cancers. In multiple primary tumours and cell models, loss of CREBBP activity resulted in upregulation of the FOXM1 transcriptional network. Strikingly, treatment with a range of CDK4/6 inhibitors (CDK4/6i), that indirectly target FOXM1 activity, selectively impaired growth in both CREBBP-altered spheroids and cell line xenografts and patient derived models from multiple tumour types. This study is the first to provide rationale for CREBBP as a biomarker for CDK4/6i response in cancer representing a new treatment paradigm for tumours that harbour CREBBP alterations that have limited therapeutic options.

2022-03-23 | PXD012098 | Pride

Hysteresis of IL-10R primes solid tumour microenvironment for bacterial immunotherapy

Project description:Hysteresis, a ubiquitous phenomenon in nonlinear systems, plays a vital role in diverse scientific disciplines. Here, we demonstrated the presence of hysteresis in the expression of interleukin-10 receptor (IL-10R) within the tumour microenvironment (TME) during bacterial immunotherapy. The engineered Salmonella enterica, administered intravenously, exhibited remarkable efficacy in multiple tumour types, effectively eliminating tumours and preventing recurrence and metastasis. We found that the hysteretic response of IL-10R can prime TME for bacterial homing and reinvigorate intratumoural CD8+ T cells. Furthermore, the differential IL-10R levels observed in different human tumour types suggest a potential correlation with clinical outcomes. Overall, our study not only uncovers the central role of hysteresis in driving the therapeutic effects of bacterial immunotherapy, but also provides a framework for intratumoural immunomodulation in solid tumour treatment.

2024-04-10 | GSE263108 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data